Andersen Peter, Doherty T Mark, Pai Madhukar, Weldingh Karin
Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
Trends Mol Med. 2007 May;13(5):175-82. doi: 10.1016/j.molmed.2007.03.004. Epub 2007 Apr 5.
In humans, Mycobacterium tuberculosis persists for long periods in a clinically latent state, creating a huge reservoir of 'silent' tuberculosis (TB) (roughly one-third of the global population) from which new cases continually arise. A prognostic marker for active TB would enable targeted treatment of the small fraction of infected individuals who are most at risk of developing contagious TB, contributing greatly to TB control efforts. Here, we propose that TB-specific interferon-gamma release assays might be useful for identifying individuals with progressive infections who are likely to develop the disease. This might provide an unprecedented advantage for TB control, namely targeted preventive therapy for individuals who are most at risk of developing active contagious TB.
在人类中,结核分枝杆菌可长期处于临床潜伏状态,形成一个巨大的“隐性”结核病(TB)储存库(约占全球人口的三分之一),新病例不断从中出现。活动性结核病的预后标志物将有助于对一小部分最有可能发展为传染性结核病的受感染个体进行靶向治疗,这将极大地推动结核病控制工作。在此,我们提出,结核特异性干扰素-γ释放试验可能有助于识别那些可能发病的进行性感染个体。这可能为结核病控制带来前所未有的优势,即对最有可能发展为活动性传染性结核病的个体进行靶向预防性治疗。